Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission
暂无分享,去创建一个
Z. Estrov | M. Andreeff | H. Kantarjian | G. Garcia-Manero | J. Cortes | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | N. Pemmaraju | N. Jain | Xuemei Wang | Sa A. Wang | A. Ferrajoli | S. Pierce | K. Naqvi | I. Abou Dalle | N. Jammal | S. Pelletier
[1] Complete Remission , 2020, Definitions.
[2] H. Döhner,et al. The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission , 2019 .
[3] T. Kadia,et al. Maintenance therapy in AML: The past, the present and the future , 2019, American journal of hematology.
[4] E. Vellenga,et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. , 2019, Blood.
[5] M. Coleman,et al. Adult leukemia survival trends in the United States by subtype: A population‐based registry study of 370,994 patients diagnosed during 1995‐2009 , 2018, Cancer.
[6] F. Ravandi,et al. Evaluating measurable residual disease in acute myeloid leukemia. , 2018, Blood advances.
[7] Sin-Ho Jung,et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Bernard,et al. Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial , 2017, Blood Cancer Journal.
[9] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[10] Asim Khwaja,et al. Acute myeloid leukaemia , 2016, Nature Reviews Disease Primers.
[11] Yashma Patel,et al. Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.
[12] D. Blaise,et al. Hematopoietic stem cell transplantation for patients with AML in first complete remission. , 2016, Blood.
[13] Christopher A. Miller,et al. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. , 2015, JAMA.
[14] A. Wei,et al. Maintenance lenalidomide in combination with 5‐azacitidine as post‐remission therapy for acute myeloid leukaemia , 2015, British journal of haematology.
[15] R. Hills,et al. A Comparison of Limited Consolidation Chemotherapy Therapy Or Not, and Demethylation Maintenance Or Not in Older Patients with Aml and High Risk Mds: Long Term Results of the Uk Ncri Aml16 Trial , 2015 .
[16] I. Lewis,et al. Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG) , 2014 .
[17] M. Boccadoro,et al. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents , 2014, Annals of Hematology.
[18] R. Hills,et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Issa,et al. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission , 2012, Leukemia.
[20] Z. Berneman,et al. Natural killer cell immune escape in acute myeloid leukemia , 2012, Leukemia.
[21] A. Verma,et al. Mechanism of action of lenalidomide in hematological malignancies , 2009, Journal of hematology & oncology.
[22] Hisashi Sakamaki,et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.
[23] P. Dickman,et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. , 2009, Blood.
[24] S. Fröhling,et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.
[25] S. Jagannath,et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.
[26] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[27] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[28] D. Grimwade,et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.